



ASX ANNOUNCEMENT

27 November 2013

RESTRICTED SECURITIES

The Board of Cynata Therapeutics Limited (ASX: CYP) provide below, the number of restricted securities subject to escrow and the escrow period applied to those securities.

The ASX codes for the Company's securities have changed as follows:

Escrow Period	Shares
12 months from date of issue being 22 November 2013	10,000,001
Total Shares Escrowed	10,000,001

Escrow Period	Options
24 months from date of reinstatement to official quotation by ASX – Unlisted Options (CYPAL), exercise price \$0.40 & expiring 27/9/18	5,000,000
24 months from date of reinstatement to official quotation by ASX – Unlisted Options (CYPAL), exercise price \$0.40 & expiring 9/9/16	500,000
Total Options Escrowed	5,500,000

Dr Ross Macdonald

Managing Director & Chief Executive Officer
+61 412 119 343

About Cynata Therapeutics Limited

Cynata Therapeutics Ltd is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.